ROSE.BA Instituto Rosenbusch S.A.
- Market cap
- ARS 5.94B
- P/E
- 0.7x
- P/B
- 0.76x
- ROE
- 60.1%
- Dividend yield
- -
- Fundamental score
- 2.0/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is ROSE.BA undervalued?
Graham numberThe Graham number of Instituto Rosenbusch S.A. cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Instituto Rosenbusch S.A. fundamental analysis
8 of 22 checks passedROE 2/2
High return on equity (60.1%), above 20%.
ROA 1/1
Return on assets (20.3%) is above the industry median (5.6%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-146.6%) is below the industry median (-3.6%).
Revenue Growth 2/2
Revenue grew 67.1% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 0/1
Current assets do not cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (34.6%), 40% or less.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 0/1
Operating cash flow does not cover 20% of total debt.
Interest Coverage 0/1
EBIT is negative, against interest expense, below 5x.
PE vs Market 1/1
PE (0.7x) is below the market median (6.7x).
PE vs Industry 1/1
PE (0.7x) is below the industry median (5.8x).
PBV 0/1
Price to book (0.8x) is above the industry median (0.8x).
Graham Number 1/1
The price is below the Graham number (PE x PB = 0.5, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Instituto Rosenbusch S.A. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Instituto Rosenbusch S.A.
Instituto Rosenbusch S.A. manufactures and sells veterinary products in Argentina. The company offers biological products, including products for reproductive-respiratory complex, IBR, BVD, brucelosis, carbuncle, and other diseases; clostridial vaccines; vaccines for cattle, sheep, goats, horses, and dogs; and products for the prevention of pneumonia and calve diarrhea, and cattle infectious keratoconjunctivitis. It also provides pharmaceutical products, such as external and…
Full company profileInstituto Rosenbusch S.A. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Instituto Rosenbusch S.A. annual financial statements (ARS; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 167M | 172M | 299M | 412M | 559M | 782M | 1.37B | 9.86B | 10.9B | 6.40B | 7.57B |
| Gross Profit | 60.7M | 57.3M | 80.8M | 135M | 188M | 222M | 642M | 2.91B | 5.04B | -599M | -377M |
| Operating Income | 12.4M | 550K | 1.00M | 21.0M | 50.7M | 8.25M | 286M | 146M | 2.56B | -3.14B | -3.11B |
| EBITDA | - | 11.4M | 41.3M | -50.5M | 53.7M | 47.5M | 235M | 2.48B | -1.02B | -2.65B | -132M |
| Net Income | 10.2M | -72.3K | 798K | -89.2M | -17.0M | -19.6M | -8.10M | 1.23B | -1.86B | -4.60B | 4.61B |
| EPS | - | 0.00 | 0.02 | -2.09 | -0.40 | -0.46 | -0.19 | 29 | -44 | -108 | 108 |
| Balance Sheet | |||||||||||
| Total Assets | 198M | 214M | 367M | 497M | 676M | 747M | 1.35B | 11.0B | 9.92B | 7.75B | 22.7B |
| Total Liabilities | 115M | 127M | 221M | 381M | 528M | 548M | 947M | 6.43B | 5.93B | 8.27B | 14.7B |
| Shareholders' Equity | 75.8M | 77.1M | 128M | 105M | 130M | 177M | 363M | 4.17B | 3.74B | -800M | 7.67B |
| Cash & Short-term Investments | 6.17M | 5.35M | 14.9M | 15.8M | 47.9M | 57.0M | 107M | 851M | 1.15B | 712M | 986M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 15.8M | -3.51M | -22.1M | 59.2M | 65.8M | 58.4M | 49.3M | 331M | 720M | 410M | 281M |
| Capital Expenditure | 15.8M | 3.01M | 1.51M | 9.84M | 2.99M | 4.18M | 26.5M | 115M | 13.6M | 12.1M | 0.00 |
| Free Cash Flow | - | -11.0M | -23.6M | 12.1M | 41.6M | 27.8M | 22.7M | 216M | 707M | 398M | 281M |
| Ratios | |||||||||||
| ROE | 13.4% | -0.1% | 0.6% | -85.1% | -13.1% | -11.1% | -2.2% | 29.4% | -49.9% | - | 60.1% |
| ROA | 5.1% | 0.0% | 0.2% | -18.0% | -2.5% | -2.6% | -0.6% | 11.2% | -18.8% | -59.4% | 20.3% |
| Net Profit Margin | 6.1% | 0.0% | 0.3% | -21.7% | -3.0% | -2.5% | -0.6% | 12.4% | -17.1% | -71.8% | 60.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Instituto Rosenbusch S.A. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | ARS 33.0M | 0.77 | - |
| 2018 | ARS 33.0M | 0.77 | 4,129.1% |
| 2017 | ARS 33.0M | 0.77 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 113.469:100 on Aug 13, 2001.
Who owns Instituto Rosenbusch S.A.
- Insiders 80.16%
- Institutions 0.00%
- Public & others 19.84%
- Shares outstanding 42.6M
- Free float 38.5M
Instituto Rosenbusch S.A. company profile
- Company name
- Instituto Rosenbusch S.A.
- Ticker
- ROSE.BA
- ISIN
- ARROSE010025
- Exchange
- Buenos Aires Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- Hipólito Yrigoyen 1628 (C1089AAF), Buenos Aires, Argentina, 1136
- Phone
- 54 11 4304 0051
- Website
- rosenbusch.com
About Instituto Rosenbusch S.A.
Instituto Rosenbusch S.A. manufactures and sells veterinary products in Argentina. The company offers biological products, including products for reproductive-respiratory complex, IBR, BVD, brucelosis, carbuncle, and other diseases; clostridial vaccines; vaccines for cattle, sheep, goats, horses, and dogs; and products for the prevention of pneumonia and calve diarrhea, and cattle infectious keratoconjunctivitis. It also provides pharmaceutical products, such as external and internal antiparasitics, endectocides, antimicotics-bacteriostatics, injectable antibiotics, antimastitics, and other chemotherapics, as well as vitamins and minerals. The company was founded in 1917 and is based in Buenos Aires, Argentina.
Instituto Rosenbusch S.A. management
2- Dr. Rodolfo Martín BalestriniChairman of the Board of Directors & President
- Oscar EcheverriaFinancial Manager